⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2020ESMO OpenOpen Access

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors

Kartik Anand Geetanjali Sahu Ethan Burns Allyne M. Ensor Joe Ensor Sai Ravi Pingali Vivek Subbiah Swaminathan P. Iyer

View Full Paper

Ask AI

Bookmark

Share

Abstract

PD-1/PD-L1 inhibitors used in the treatment of cancer subtypes is associated with increased TB and AMI risk. Although this complication is rare, clinicians using PD-1/PD-L1 inhibitors should be aware of the risks.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anand et al. (2020) studied this question.

synapsesocial.com/papers/69df46f6d5404a0bea592be5 https://doi.org/10.1136/esmoopen-2020-000866

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measureESMO Open · Tue,
2Adjuvant therapy for RCC: considerations beyond survival metricsESMO Open · Tue,
3Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE projectESMO Open · Tue,
4“Our patients deserve better”—roadblocks to optimal care in biliary malignanciesESMO Open · Tue,
5A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomasESMO Open · Tue,

More from ESMO Open

Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trialFri,
The cost of intensification in high-risk non–muscle-invasive bladder cancerFri,
Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gapsWed,
Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroupsWed,
Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinomaWed,